Premium
Antenatal corticosteroid treatment in singleton, small‐for‐gestational‐age infants born at 24–31 weeks’ gestation: a population‐based study
Author(s) -
RiskinMashiah S,
Riskin A,
Bader D,
Kugelman A,
Boyko V,
LernerGeva L,
Reichman B
Publication year - 2016
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/1471-0528.13723
Subject(s) - singleton , gestation , medicine , gestational age , corticosteroid , small for gestational age , population , pediatrics , obstetrics , pregnancy , endocrinology , biology , genetics , environmental health
Objective To assess the impact of antenatal corticosteroid therapy on mortality and severe morbidities in preterm, small‐for‐gestational‐age ( SGA ) neonates compared with preterm non‐ SGA neonates. Design Population‐based study. Setting/population Israel National Very Low Birth Weight infant database from 1995–2012. Methods Singleton infants of 24–31 weeks’ gestation, without major malformations. Antenatal corticosteroids were considered either any treatment or no treatment. Main outcome measures Univariate and multivariable logistic regression analyses were performed to assess the effect of antenatal corticosteroids on neonatal mortality and a composite adverse outcome of mortality or severe neonatal morbidity. Results Among the 10 887 study infants, 1771 were SGA . Of these, 70.4% of SGA and 66.7% of non‐ SGA neonates were exposed to antenatal corticosteroids. Among SGA neonates, antenatal corticosteroids were associated with decreased mortality (32.2 versus 19.3%, P < 0.0001) and composite adverse outcome (54.1 versus 43.4%, P < 0.0001), similar to the effect in non‐ SGA neonates (mortality 26.7 versus 12.2%, P < 0.0001; composite outcome 50.5 versus 34.6%, P < 0.0001). Multivariable logistic regression analyses demonstrated a 50% reduction in mortality risk among SGA and 57% reduction in non‐ SGA neonates exposed to corticosteroids [ OR = 0.50, 95% confidence interval (95% CI ) 0.39–0.64 and OR = 0.43, 95% CI 0.38–0.47, respectively], P ‐value for interaction = 0.08. Composite adverse outcome risk was significantly reduced in SGA ( OR = 0.67, 95% CI 0.54–0.83) and non‐ SGA infants ( OR = 0.57, 95% CI 0.52–0.63), P ‐value for interaction = 0.04. Conclusions Antenatal corticosteroids significantly reduced mortality and severe morbidities among preterm SGA neonates, with slightly a less pronounced effect compared with non‐ SGA preterm infants. Antenatal corticosteroids should be given to fetuses suspected of intrauterine growth retardation, at risk for preterm delivery, in order to improve perinatal outcome. Tweetable abstract Antenatal steroids reduced mortality and severe morbidities among singleton, preterm SGA neonates.